[go: up one dir, main page]

MX2017011189A - Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos. - Google Patents

Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos.

Info

Publication number
MX2017011189A
MX2017011189A MX2017011189A MX2017011189A MX2017011189A MX 2017011189 A MX2017011189 A MX 2017011189A MX 2017011189 A MX2017011189 A MX 2017011189A MX 2017011189 A MX2017011189 A MX 2017011189A MX 2017011189 A MX2017011189 A MX 2017011189A
Authority
MX
Mexico
Prior art keywords
dsbc
dsba
methods
ultrapurified
prepare
Prior art date
Application number
MX2017011189A
Other languages
English (en)
Other versions
MX381844B (es
Inventor
Lim Amy
T Yee Liliana
B Fong Chris
Wong Marc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2017011189A publication Critical patent/MX2017011189A/es
Publication of MX381844B publication Critical patent/MX381844B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/04—Oxidoreductases acting on sulfur groups as donors (1.8) with a disulfide as acceptor (1.8.4)
    • C12Y108/04002—Protein-disulfide reductase (glutathione) (1.8.4.2), i.e. BdbC or BdbD
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/04—Intramolecular oxidoreductases (5.3) transposing S-S bonds (5.3.4)
    • C12Y503/04001—Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90212—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención proporciona métodos para producir polipéptidos de disulfuro oxidorreductasa A (DsbA) y de disulfuro oxidorreductasa C (DsbC) a niveles muy altos de pureza. También se proporcionan DsbA y DsbC ultrapuros y métodos para utilizarlos, por ejemplo, para utilizar en inmunoensayos para mostrar la eliminación de DsbA y DsbC de componentes biológicos producidos en la bacteria.
MX2017011189A 2015-03-06 2016-03-04 Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos MX381844B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562129701P 2015-03-06 2015-03-06
PCT/US2016/021059 WO2016144824A1 (en) 2015-03-06 2016-03-04 Ultrapurified dsba and dsbc and methods of making and using the same

Publications (2)

Publication Number Publication Date
MX2017011189A true MX2017011189A (es) 2018-01-23
MX381844B MX381844B (es) 2025-03-13

Family

ID=55637452

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000153A MX387454B (es) 2015-03-06 2016-03-04 DsbA Y DsbC ULTRAPURIFICADO Y MÉTODOS PARA ELABORARLOS Y UTILIZARLOS.
MX2017011189A MX381844B (es) 2015-03-06 2016-03-04 Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021000153A MX387454B (es) 2015-03-06 2016-03-04 DsbA Y DsbC ULTRAPURIFICADO Y MÉTODOS PARA ELABORARLOS Y UTILIZARLOS.

Country Status (17)

Country Link
US (2) US10073098B2 (es)
EP (2) EP3265557B1 (es)
JP (2) JP6865689B2 (es)
KR (1) KR20170122216A (es)
CN (1) CN107531749A (es)
AR (1) AR103852A1 (es)
AU (1) AU2016230018A1 (es)
CA (1) CA2978256A1 (es)
ES (1) ES2761726T3 (es)
HK (1) HK1247936A1 (es)
HR (1) HRP20192217T1 (es)
IL (1) IL254166A0 (es)
MX (2) MX387454B (es)
PL (1) PL3265557T3 (es)
SG (2) SG10202005917SA (es)
SI (1) SI3265557T1 (es)
WO (1) WO2016144824A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
ES2761726T3 (es) 2015-03-06 2020-05-20 Hoffmann La Roche DsbA y DsbC ultrapurificadas y procedimientos de preparación y uso de las mismas
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
AR119264A1 (es) * 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
KR20220166814A (ko) 2020-04-09 2022-12-19 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 항체를 함유하는 조성물
EP4197612B1 (en) * 2021-12-17 2025-08-13 Dionex Corporation Desalting system for chromatography
CN115028691B (zh) * 2022-06-29 2024-09-10 青岛硕景生物科技有限公司 一种检测试纸用的独立质控系统、杂交瘤细胞株、质控线用包被单克隆抗体及其应用
CN119874933A (zh) * 2024-11-20 2025-04-25 金宇保灵生物药品有限公司 一种基于大肠杆菌的纳米抗体融合表达体系及其制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (es) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
GB9325718D0 (en) * 1993-12-16 1994-02-16 Ars Holding 89 Nv Sensor device for sandwich assay
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6027888A (en) 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
JP2000083670A (ja) * 1998-09-09 2000-03-28 Hsp Kenkyusho:Kk ＤｓｂＡ／ＤｓｂＢ／ＤｓｂＣ／ＤｓｂＤ発現プラスミド
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2364568A1 (en) * 1999-03-17 2000-09-21 Adrian Woolfson Method for refolding molecules of polypeptides containing ig domains
US6872563B1 (en) * 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
EP2857516B1 (en) 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
JP4309656B2 (ja) 2000-12-14 2009-08-05 ジェネンテック・インコーポレーテッド 原核生物で生成させた抗体とその用途
EP1345967B1 (en) 2000-12-22 2011-08-10 Grad, Carole, Legal representative of Kaplan, Howard Phage display libraries of human v h fragments
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
DK1718677T3 (da) 2003-12-19 2012-07-09 Genentech Inc Monovalente antistoffragmenter egnede som terapeutiske midler
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
CN100475965C (zh) 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
KR101431856B1 (ko) * 2007-01-22 2014-08-27 제넨테크, 인크. 항체의 고분자전해질 침전 및 정제
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
CA2780143A1 (en) * 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
AU2010201410B2 (en) * 2010-03-30 2015-04-30 Pelican Technology Holdings, Inc. High level expression of recombinant CRM197
GB201012519D0 (en) 2010-07-26 2010-09-08 Ucl Business Plc Method and system for anomaly detection in data sets
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
AU2012323995B2 (en) * 2011-11-02 2016-06-09 Genentech, Inc. Overload and elute chromatography
EP2986731B1 (en) * 2013-04-19 2022-05-18 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
PL3044323T3 (pl) * 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
ES2761726T3 (es) 2015-03-06 2020-05-20 Hoffmann La Roche DsbA y DsbC ultrapurificadas y procedimientos de preparación y uso de las mismas

Also Published As

Publication number Publication date
US10073098B2 (en) 2018-09-11
CA2978256A1 (en) 2016-09-15
HK1247936A1 (zh) 2018-10-05
JP7191132B2 (ja) 2022-12-16
ES2761726T3 (es) 2020-05-20
PL3265557T3 (pl) 2020-03-31
MX387454B (es) 2025-03-18
CN107531749A (zh) 2018-01-02
SG11201707186YA (en) 2017-10-30
US10690671B2 (en) 2020-06-23
MX2021000153A (es) 2021-10-28
EP3636749A1 (en) 2020-04-15
EP3636749B1 (en) 2022-04-27
EP3265557B1 (en) 2019-10-16
US20190056399A1 (en) 2019-02-21
SG10202005917SA (en) 2020-07-29
JP6865689B2 (ja) 2021-04-28
AU2016230018A1 (en) 2017-09-21
IL254166A0 (en) 2017-10-31
HRP20192217T1 (hr) 2020-02-21
EP3265557A1 (en) 2018-01-10
KR20170122216A (ko) 2017-11-03
JP2018516229A (ja) 2018-06-21
AR103852A1 (es) 2017-06-07
US20160370369A1 (en) 2016-12-22
JP2021078502A (ja) 2021-05-27
MX381844B (es) 2025-03-13
SI3265557T1 (sl) 2020-02-28
WO2016144824A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
MX2017011189A (es) Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos.
CL2019003270A1 (es) Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2018002754A1 (es) Proceso de produccion de raav a base de columnas completamente escalable.
MX2022012374A (es) Composiciones multi-suplementos.
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
BR112019012343A2 (pt) anticorpos il-11ra
BR112017007636A2 (pt) métodos para a preparação de ribosídeos
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
MX2024001617A (es) Composiciones biofarmaceuticas.
SA520412669B1 (ar) تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية
MX381278B (es) Composición para la estimulación ovárica controlada.
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
BR112016015218A2 (pt) microrganismo com capacidade melhorada de produção de l-treonina e método para produzir l-treonina com o uso desse
BR112017022073A2 (pt) método para purificação de proteína
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2016010950A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MX2020004093A (es) Puzolana de vidrio activada.
CL2017001633A1 (es) Método de manufactura de proteína.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2020012065A (es) Compuestos de ciclopentano.
MX2018011193A (es) Proteinas derivadas de alfa-1-microglobulina novedosas y su uso.
MX2021013117A (es) Composiciones y metodos para el tratamiento del cancer.
CL2016002256A1 (es) Un proceso mejorado para la preparación de exametazima